Holen Sie sich die Stockscreener-App
7.10
1.23%
0.10
Schlusskurs vom Vortag:
$7.00
Offen:
$6.96
24-Stunden-Volumen:
329.55K
Relative Volume:
0.35
Marktkapitalisierung:
$364.08M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-54.19M
KGV:
-2.7519
EPS:
-2.58
Netto-Cashflow:
$-37.34M
1W Leistung:
-1.99%
1M Leistung:
+4.98%
6M Leistung:
+22.60%
1J Leistung:
+35.23%
1-Tages-Spanne:
$6.94
$7.145
1-Wochen-Bereich:
$6.70
$7.5401
52-Wochen-Spanne:
$3.9328
$7.5401
Abeona Therapeutics Inc Stock (ABEO) Company Profile
Firmenname
Abeona Therapeutics Inc
Sektor
Branche
Telefon
646-813-4701
Adresse
6555 CARNEGIE AVE, 4TH FLOOR, CLEVELAND, NY
Vergleichen Sie ABEO mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ABEO
Abeona Therapeutics Inc
|
7.10 | 353.49M | 0 | -54.19M | -37.34M | -2.58 |
|
VRTX
Vertex Pharmaceuticals Inc
|
396.85 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
603.58 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
465.66 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
667.34 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
310.45 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Abeona Therapeutics Inc Stock (ABEO) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-06-02 | Fortgesetzt | Oppenheimer | Outperform |
| 2025-03-05 | Eingeleitet | Oppenheimer | Outperform |
| 2024-07-03 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-05-30 | Eingeleitet | Stifel | Buy |
| 2020-11-11 | Hochstufung | Cantor Fitzgerald | Neutral → Overweight |
| 2020-09-18 | Eingeleitet | B. Riley FBR | Buy |
| 2020-02-10 | Eingeleitet | SVB Leerink | Outperform |
| 2019-12-10 | Fortgesetzt | Cantor Fitzgerald | Neutral |
| 2019-08-15 | Herabstufung | Maxim Group | Buy → Hold |
| 2019-08-12 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2019-07-26 | Herabstufung | Mizuho | Buy → Neutral |
| 2019-06-27 | Eingeleitet | Mizuho | Buy |
| 2018-10-12 | Eingeleitet | Mizuho | Buy |
| 2018-06-05 | Eingeleitet | Seaport Global Securities | Buy |
| 2017-11-08 | Eingeleitet | SunTrust | Buy |
| 2017-10-16 | Bestätigt | H.C. Wainwright | Buy |
| 2017-10-11 | Bestätigt | Cantor Fitzgerald | Overweight |
| 2017-10-10 | Eingeleitet | Citigroup | Buy |
| 2017-10-05 | Bestätigt | Maxim Group | Buy |
| 2017-09-15 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2017-07-18 | Bestätigt | Maxim Group | Buy |
| 2017-06-22 | Fortgesetzt | Jefferies | Buy |
| 2017-01-06 | Eingeleitet | Jefferies | Buy |
| 2016-09-29 | Bestätigt | Maxim Group | Buy |
Alle ansehen
Abeona Therapeutics Inc Aktie (ABEO) Neueste Nachrichten
Chartists See Breakout Potential in Abeona Therapeutics Inc.July 2025 WrapUp & High Accuracy Swing Entry Alerts - newsyoung.net
Institutional scanner results for Abeona Therapeutics Inc.2025 Winners & Losers & AI Driven Stock Reports - Newser
Abeona Therapeutics Inc. (NASDAQ:ABEO) Q2 2025 Earnings Call Transcript - Insider Monkey
What to expect from Abeona Therapeutics Inc. in the next 30 daysJuly 2025 WrapUp & Real-Time Volume Trigger Notifications - Newser
Using economic indicators to assess Abeona Therapeutics Inc. potential2025 Technical Overview & Stock Portfolio Risk Management - Newser
Backtesting results for Abeona Therapeutics Inc. trading strategiesQuarterly Market Review & Daily Profit Maximizing Trade Tips - Newser
Leading vs lagging indicators on Abeona Therapeutics Inc. performanceQuarterly Market Summary & Verified Chart Pattern Signals - Newser
Real time breakdown of Abeona Therapeutics Inc. stock performancePortfolio Gains Summary & Stepwise Entry/Exit Trade Alerts - Newser
What MACD and RSI say about Abeona Therapeutics Inc.July 2025 PreEarnings & Reliable Breakout Stock Forecasts - Newser
What’s the recovery path for long term holders of Abeona Therapeutics Inc.2025 Breakouts & Breakdowns & Advanced Technical Signal Analysis - Newser
Abeona Therapeutics Inc.’s volatility index tracking explained2025 Geopolitical Influence & AI Driven Price Predictions - Newser
What the charts say about Abeona Therapeutics Inc. todayShare Buyback & AI Powered Market Entry Ideas - Newser
How to forecast Abeona Therapeutics Inc. trends using time series2025 Growth vs Value & Scalable Portfolio Growth Methods - Newser
What technical models suggest about Abeona Therapeutics Inc.’s comebackStop Loss & Weekly High Return Opportunities - Newser
Abeona Therapeutics (ABEO) Gets a Buy from H.C. Wainwright - The Globe and Mail
ABEO: First Patient Treatment with Zevaskyn Expected in 3Q25 - Research Tree
Abeona Therapeutics Inc. stock trend outlook and recovery pathTrade Signal Summary & Capital Efficient Trading Techniques - Newser
Can Abeona Therapeutics Inc. maintain sales growthPortfolio Gains Summary & Accurate Intraday Trading Signals - thegnnews.com
Will Abeona Therapeutics Inc. continue its uptrendJuly 2025 Fed Impact & Daily Stock Trend Reports - Newser
Abeona Therapeutics Inc. stock chart pattern explainedEarnings Performance Report & Weekly Sector Rotation Insights - Newser
Abeona Therapeutics Executives Offload Stock Amid Financial Turnaround - AInvest
Top Executives Offload Abeona Therapeutics Stock in Major Transactions - TipRanks
Abeona Therapeutics director Crombez sells $33k in shares - Investing.com
Abeona Therapeutics director Crombez sells $33k in shares By Investing.com - Investing.com South Africa
Abeona Therapeutics CFO sells $110k in stock - Investing.com India
Abeona Therapeutics CFO sells $110k in stock By Investing.com - Investing.com UK
Abeona Therapeutics: AAV204 Capsid Licensing as a New Growth Engine - AInvest
Abeona Therapeutics: AAV204 Capsid Could Be Next Growth Prospect Beyond Zevaskyn (ABEO) - Seeking Alpha
Abeona Therapeutics price target raised to $20 from $19 at Oppenheimer - TipRanks
How to read the order book for Abeona Therapeutics Inc.Market Risk Analysis & Reliable Price Action Trade Plans - Newser
Oppenheimer Adjusts Abeona Therapeutics Price Target to $20 From $19, Maintains Outperform Rating - MarketScreener
Earnings call transcript: Abeona Therapeutics Q2 2025 reports unexpected profit - Investing.com
Abeona Therapeutics: Q2 Earnings Snapshot - Stamford Advocate
Screener Results Flag Abeona Therapeutics Inc. as OversoldJuly 2025 PreEarnings & AI Forecasted Stock Moves - beatles.ru
Abeona Posts Q2 Profit on Asset Sale - AOL.com
Abeona Therapeutics Reports Strong Financial Turnaround - TipRanks
Abeona Therapeutics Inc. stock outlook for YEARPortfolio Growth Summary & Stepwise Trade Execution Plans - Newser
Abeona Therapeutics Inc. Breaks Losing Streak — Is the Trend ReversingCEO Change & AI Enhanced Trading Alerts - beatles.ru
Abeona Therapeutics' Q2 2025 Earnings: A Catalyst-Driven Path to Commercialization and Profitability - AInvest
Transcript : Abeona Therapeutics Inc., Q2 2025 Earnings Call, Aug 14, 2025 - MarketScreener
Abeona Therapeutics reports Q2 EPS ($1.71) vs (26c) last year - TipRanks
Abeona Therapeutics Shakes Off Losses With A Surprise Profit - Finimize
Abeona Therapeutics shares rise 6.71% premarket after reporting Q2 net income of $108.8 million, beating Wall Street expectations. - AInvest
Abeona Therapeutics Receives FDA Approval for ZEVASKYN™: First Autologous Gene Therapy for Recessive Dystrophic Epidermolysis Bullosa with Launch Expected in 2025 - Quiver Quantitative
Abeona Therapeutics Q2 net income beats estimates on PRV sale, sees profitability in H1 2026 - MarketScreener
ABEONA THERAPEUTICS INC. SEC 10-Q Report - TradingView
Abeona Therapeutics® Reports Second Quarter 2025 Financial Results and Corporate Updates - GlobeNewswire
Finanzdaten der Abeona Therapeutics Inc-Aktie (ABEO)
Umsatz
Nettogewinn
Free Cashflow
ENV
Abeona Therapeutics Inc-Aktie (ABEO) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Vazzano Joseph Walter | Chief Financial Officer |
Aug 15 '25 |
Sale |
7.36 |
15,000 |
110,358 |
462,666 |
0.88%
0.59%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):